 |
Albendazole |
|---|---|
| Trade Name | Albenza |
| Orphan Indication | Neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis |
| USA Market Approval | USA |
| USA Designation Date | 1996-01-18 00:00:00 |
| Sponsor | Amedra Pharmaceuticals LLC;2 Walnut Grove Drive, Suite 190;Horsham, Pennsylvania, 19044 |
